Technology Development for Next Generation Functional Analysis of Bioactive Molecules

The genome-wide HaploInsufficieny Profiling (HIPHOP) technique has been validated as a method to quantify the relative abundance of uniquely tagged yeast deletion strains using a microarray readout. The massive throughput of next generation sequencing presents a new technology for assessing HIPHOP p...

Full description

Bibliographic Details
Main Author: Smith, Andrew Michael
Other Authors: Giaever, Guri
Language:en_ca
Published: 2011
Subjects:
Online Access:http://hdl.handle.net/1807/31941
id ndltd-TORONTO-oai-tspace.library.utoronto.ca-1807-31941
record_format oai_dc
spelling ndltd-TORONTO-oai-tspace.library.utoronto.ca-1807-319412013-04-19T19:56:26ZTechnology Development for Next Generation Functional Analysis of Bioactive MoleculesSmith, Andrew MichaelYeastSequencingTechnology DevelopmentChemical BiologyChemical GeneticsDrug DiscoveryThe genome-wide HaploInsufficieny Profiling (HIPHOP) technique has been validated as a method to quantify the relative abundance of uniquely tagged yeast deletion strains using a microarray readout. The massive throughput of next generation sequencing presents a new technology for assessing HIPHOP profiles. I developed a new method called Barcode analysis by Sequencing (Bar-seq) that applies deep sequencing to genome-scale fitness. I show that Bar-seq outperforms the current benchmark barcode microarray assay in terms of both dynamic range and throughput. When applied to a complex genome-scale fitness assay, Bar-seq quantitatively identifies drug-targets, exceeding the performance of the microarray assay. I also established that Bar-seq is well suited to a multiplex format and provides a dramatic increase in throughput. I used the genome-wide HIPHOP assay and other functional genomics tools to explore the mechanisms underlying drug-drug synergies. Drug combination therapy, and synergistic combinations in particular, have several advantages over monotherapies. Synergistic drug combinations allow the dose of each agent to be reduced, often with the benefit of diminishing side effects while maintaining efficacy and decreasing the chances of drug resistance. I used my yeast model to identify synergistic drug combinations and found that inhibitors of ergosterol biosynthesis are highly synergistic with several agents, including those targeting other points within the same pathway. I also devised a method that enriches for synergistic interactions during screening of compound combinations. This new synergy prediction method can aid in the rapid identification of anti-proliferative combinations and can be readily applied to other organisms for further characterization and/or confirmation. Finally, I examined synergistic combination HIPHOP profiles and identified Gene Ontology enrichments that are combination-specific.Giaever, GuriBoone, Charles2011-112012-01-11T20:48:26ZNO_RESTRICTION2012-01-11T20:48:26Z2012-01-11Thesishttp://hdl.handle.net/1807/31941en_ca
collection NDLTD
language en_ca
sources NDLTD
topic Yeast
Sequencing
Technology Development
Chemical Biology
Chemical Genetics
Drug Discovery
spellingShingle Yeast
Sequencing
Technology Development
Chemical Biology
Chemical Genetics
Drug Discovery
Smith, Andrew Michael
Technology Development for Next Generation Functional Analysis of Bioactive Molecules
description The genome-wide HaploInsufficieny Profiling (HIPHOP) technique has been validated as a method to quantify the relative abundance of uniquely tagged yeast deletion strains using a microarray readout. The massive throughput of next generation sequencing presents a new technology for assessing HIPHOP profiles. I developed a new method called Barcode analysis by Sequencing (Bar-seq) that applies deep sequencing to genome-scale fitness. I show that Bar-seq outperforms the current benchmark barcode microarray assay in terms of both dynamic range and throughput. When applied to a complex genome-scale fitness assay, Bar-seq quantitatively identifies drug-targets, exceeding the performance of the microarray assay. I also established that Bar-seq is well suited to a multiplex format and provides a dramatic increase in throughput. I used the genome-wide HIPHOP assay and other functional genomics tools to explore the mechanisms underlying drug-drug synergies. Drug combination therapy, and synergistic combinations in particular, have several advantages over monotherapies. Synergistic drug combinations allow the dose of each agent to be reduced, often with the benefit of diminishing side effects while maintaining efficacy and decreasing the chances of drug resistance. I used my yeast model to identify synergistic drug combinations and found that inhibitors of ergosterol biosynthesis are highly synergistic with several agents, including those targeting other points within the same pathway. I also devised a method that enriches for synergistic interactions during screening of compound combinations. This new synergy prediction method can aid in the rapid identification of anti-proliferative combinations and can be readily applied to other organisms for further characterization and/or confirmation. Finally, I examined synergistic combination HIPHOP profiles and identified Gene Ontology enrichments that are combination-specific.
author2 Giaever, Guri
author_facet Giaever, Guri
Smith, Andrew Michael
author Smith, Andrew Michael
author_sort Smith, Andrew Michael
title Technology Development for Next Generation Functional Analysis of Bioactive Molecules
title_short Technology Development for Next Generation Functional Analysis of Bioactive Molecules
title_full Technology Development for Next Generation Functional Analysis of Bioactive Molecules
title_fullStr Technology Development for Next Generation Functional Analysis of Bioactive Molecules
title_full_unstemmed Technology Development for Next Generation Functional Analysis of Bioactive Molecules
title_sort technology development for next generation functional analysis of bioactive molecules
publishDate 2011
url http://hdl.handle.net/1807/31941
work_keys_str_mv AT smithandrewmichael technologydevelopmentfornextgenerationfunctionalanalysisofbioactivemolecules
_version_ 1716582150734610432